Results 61 to 70 of about 1,220 (100)

卵巢癌患者血清ROMA、CA125、HE4联合检测的临床意义

Zhongguo shiyan zhenduanxue, 2017
卵巢癌是女性生殖系统恶性肿瘤,晚期患者5年生存率较低,预后较差[1]。目前卵巢癌的辅助诊断血清学指标常用糖类抗原125（CA125）[2],附睾蛋白4（HE4）是临床常用的另一种辅助的诊断肿瘤标记物,具有较高的特异性和敏感性[3]。卵巢恶性肿瘤风险预测值（ROMA）是近年来临床提出的一种新的预测卵巢癌的指标 ...
孔琪
doaj  

卵巢高级别浆液性癌肉瘤样癌分化1例

Zhongguo shiyan zhenduanxue
卵巢肿瘤组织类型复杂，卵巢癌肉瘤极为罕见。根据WHO制定的女性生殖系统肿瘤组织学分类(2014版),上皮性肿瘤占卵巢恶性肿瘤的85%～90%,高级别浆液性癌作为Ⅱ型卵巢上皮性癌，肿瘤生长迅速，预后不良。卵巢癌肉瘤为恶性混合性中胚层肿瘤中的一种，组织中含有恶性上皮成分及肉瘤成分。本文结合吉林大学中日联谊医院妇科收治1名卵巢高级别浆液性癌局部肉瘤样癌分化患者，提高对该疾病的认识及探索治疗上的新方法。1 临床资料患者女性 ...
王皓莹, 王雪, 冷维春
doaj  

β2-微球蛋白检测与卵巢癌相关性的研究

Zhongguo shiyan zhenduanxue, 2011
目的研究β2-微球蛋白在卵巢癌患者血液、尿液中的变化。方法选择在我院住院的卵巢癌组患者68例,卵巢良性肿瘤组患者65例,正常卵巢患者组60例。分别在手术前或者检查身体时抽取静脉血和留取尿液。采用免疫透射比浊法检测三组患者血液和尿液中β2-微球蛋白（β2-MG）的水平。比较卵巢癌不同分期、分级患者血/尿β2-MG的变化。结果卵巢癌患者血液中β2-MG（4.87±0.64）和尿液中β2-MG（4.86±0.72）明显高于卵巢良性肿瘤组血液中β2-MG（2.69±0.36）和尿液中β2-MG（2.73±0 ...
徐晓宏, 张伟, 王立新
doaj  

[Development and functional validation of a nano-delivery system of miR-16/polypeptide targeting ovarian cancer cells]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao, 2021
Li Q, Cen B, Huang W, Chen J, Chen Z, Pang J, Fu W, He S, Ji A.   +8 more
europepmc   +1 more source

[A Transformer-based model using laboratory indicators efficiently differentiates ovarian cancer]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
Tan S, Zhuo L, Zeng M, Huang F, Zhu J, Cai G, Zhen X.   +6 more
europepmc   +1 more source

[Identification of Hub Genes for Ovarian Cancer Stem Cell Properties with Weighted Gene Co-expression Network Analysis]. [PDF]

Sichuan Da Xue Xue Bao Yi Xue Ban, 2021
Luo M, Zeng H, Ma XY, Ma XL.
europepmc   +1 more source

A multi-constraint representation learning model for identification of ovarian cancer with missing laboratory indicators. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
Lu Z, Huang F, Cai G, Liu J, Zhen X.
europepmc   +1 more source

Single-cell transcriptomics reveals tumor landscape in ovarian carcinosarcoma. [PDF]

J Zhejiang Univ Sci B
Xu J, Tu M.
europepmc   +1 more source

[WW domain-containing ubiquitin E3 ligase 1 regulates immune infiltration in tumor microenvironment of ovarian cancer]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
Guo X, DU R, Chen L, Guo K, Zhou B, Bian H, Han L.   +6 more
europepmc   +1 more source

RAD51B-AS1 promotes the malignant biological behavior of ovarian cancer through upregulation of RAD51B. [PDF]

J Zhejiang Univ Sci B
Wei X, Wang C, Tang S, Yang Q, Shen Z, Zhu J, Cheng X, Wang X, Xie X, Xu J, Lu W.   +10 more
europepmc   +1 more source